Skip to content

Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication

Resynchronization in Paced Heart Failure Patients With ICD Indication

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01415024
Acronym
CRTICD Dual LV
Enrollment
30
Registered
2011-08-11
Start date
2011-05-31
Completion date
Unknown
Last updated
2011-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Left Bundle-Branch Block

Keywords

CRT, Dual LV, Triple Ventricle stimulation, two leftventricular leads, Av VV optimization, Lv dp/dt measurement

Brief summary

Today patients with a Cardiac Resynchronization Therapy (CRT) indication usually receive 2 ventricular leads, right ventricular (RV) apex and left ventricular (LV) (postero-) lateral, gaining a responder rate of approximately 70%. However, the physiological agitation of the left ventricle takes place over two pathways. Therefore single point stimulation might be insufficient for a dilated, insufficiently and asynchronously contracting left ventricle, resulting in either insufficient or no response to the therapy. In the CRT ICD Dual LV study the patients receive a second LV lead in an anterior vein. When this lead is placed, temporary dual LV stimulation is started. To assess the effectivity of the dual LV lead stimulation intraoperatively a LV dp/dt-pressure measurement is taken. If there is an increase in LV dp/dt, the patients will be stimulated with both leads permanently. If not they will be stimulated conventionally. The patients participating in this study are monitored for 12 months after implantation.

Interventions

PROCEDUREsecond LV lead in CRT

second LV lead in CRT

Sponsors

Medtronic
CollaboratorINDUSTRY
Schuechtermann-Klinik
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* EF less than 35 percent * CAD or dilatative Cardiomyopathy * Sinus rhythm * NYHA III or IV, stable recompensated * QRS more than 120ms * LBBB * Patient signed Consent Form * Age more than 18 and less than 80 y

Exclusion criteria

* permanent atrial Fibrillation * permanent AV-Block II or III * Tricuspidal- and or artificial aortic valve * Indication for ACB or ACB less than 3 months ago * myocardial infarction less than 3 months * hypertrophic obstructive Cardiomyopathy; constrictive Pericarditis * heartfailure with iv catecholamine therapy * Manifested, uncontrolled, Hypo- oder Hyperthyreosis * Severe renal insufficiency with Creatinine more than 2,5 mg per dL * patients, who did not sign the consent form * General medical conditions, which restrict the patient compliance * Participation in another study * life expectancy less than 1 y * Age less than 18 y or more than 80y * Pregnant women or Women of childbearing age

Design outcomes

Primary

MeasureTime frame
LV dp/dt pressure during dual LV CRT stimulation vs. conventional biventricular pacingImplantation with pressure measurement will take place in the first week

Secondary

MeasureTime frame
Leftventricular endsystolic volume12 month

Countries

Germany

Contacts

Primary ContactWolfgang Kranig, MD
wkranig@schuechtermann-klinik.de+49-5424-6410
Backup ContactRainer Grove, MD
rgrove@schuechtermann-klinik.de+49-5424-6410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026